A case of food-dependent exerciseinduced anaphylaxis by shrimp: fructose 1,6-bisphosphate aldolase is supposed as causative component despite negative allergen-specific IgE test (ImmunoCAP). Arerugi. 2019;68(1):48e53. 10. Kimura H, Inami M, Hamaguchi Y, et al. Food-dependent exercise-induced anaphylaxis due to shrimp associated with 43 kDa, a new antigen. J Dermatol. 2018;45(3):366e367.

Studies of the association between porphyria cutanea tarda (PCT) and primary liver cancer have produced conflicting reports. The incidence of this liver tumor was studied in 138 PCT patients (7.2%) and in 358 non‐porphyric cirrhotic patients (5.6%), and no statistically significant differences were found between them (p>0.5). Nevertheless the incidence of such association was significantly higher (chi square=10.91, p<0.001) in the PCT group (24.3%) than in the non‐porphyric cirrhotic group (6.7%) when only males with underlying liver cirrhosis were considered. These results suggest that the high incidence of liver tumor in PCT is not merely related to hepatic cirrhosis. The cause of such as association remains unclear. Primary liver cancer may reveal a prior deficiency in uroporphyrinogen‐decarboxylase, but the possibility that the enzyme abnormalities were caused by the liver carcinoma also exists.

Although biologics have demonstrated to be effective in T2-high asthma patients, there is little experience with these drugs in asthma–COPD overlap (ACO). The aim of this study was to compare the effectiveness of biologics in these two conditions. We included 318 patients (24 ACO and 297 asthma) treated with monoclonal antibodies and followed for at least 12 months. Omalizumab was the most frequently employed biologic agent both in patients with ACO and asthma. Asthma control test (ACT) scores after at least 12 months of biologic therapy were not significantly different between groups. The percentage of patients with ≥1 exacerbation and ≥1 corticosteroid burst was significantly higher in ACO patients (70.8 vs 27.3 and 83.3% vs 37.5%, respectively), whereas the percentage of “controlled” patients (with no exacerbations, no need for corticosteroids and ACT ≥ 20) was significantly lower (16.7% vs 39.7%). In conclusion, this report suggests that patients with ACO treated with biologics reach worse outcomes than asthma patients.

No abstract

No abstract